References
- Abdelrahman, Aly M., Yousuf M. Al Suleimani, Priyadarsini Manoj, Mohammed Ashique, Badreldin H. Ali, and Nicole Schupp. 2020. “Effect of Infliximab, a Tumor Necrosis Factor-Alpha Inhibitor, on Doxorubicin-Induced Nephrotoxicity in Rats.” Naunyn-Schmiedeberg's Archives of Pharmacology 393 (1): 121–130. doi:https://doi.org/10.1007/s00210-019-01719-x.
- Agudelo, C. W., G. Samaha, and I. Garcia-Arcos. 2020. “Alveolar Lipids in Pulmonary Disease. A Review.” Lipids in Health and Disease 19 (1): 122. doi:https://doi.org/10.1186/s12944-020-01278-8.
- Allen, T. M., W. W. K. Cheng, J. I. Hare, and K. M. Laginha. 2006. “Pharmacokinetics and Pharmacodynamics of Lipidic Nano-Particles in Cancer.” Anti-Cancer Agents in Medicinal Chemistry 6 (6): 513–523. doi:https://doi.org/10.2174/187152006778699121.
- Amorim Biondo, L., E. Alves Lima Jr., C. Oliveira Souza, M. M. Cruz, R. D. C. Cunha, M. I. Alonso-Vale, L. M. Oyama, et al. 2016. “Impact of Doxorubicin Treatment on the Physiological Functions of White Adipose Tissue.” PLOS One 11 (3): e0151548. doi:https://doi.org/10.1371/journal.pone.0151548.
- Ando, A., K. Nitta, I. Ando, S. Sanada, S. Katsuda, N. Tonami, T. Hiraki, K. Hisada, and H. Ogawa. 1990. “Mechanism of Gallium 67 Accumulation in Inflammatory Tissue.” European Journal of Nuclear Medicine 17 (1–2): 21–27. doi:https://doi.org/10.1007/BF00819399.
- Aston, W. J., D. E. Hope, A. K. Nowak, B. W. Robinson, R. A. Lake, and W. J. Lesterhuis. 2017. “A Systematic Investigation of the Maximum Tolerated Dose of Cytotoxic Chemotherapy with and without Supportive Care in Mice.” BMC Cancer 17 (1): 684. doi:https://doi.org/10.1186/s12885-017-3677-7.
- Bagchi, D. P., and O. A. MacDougald. 2019. “Identification and Dissection of Diverse Mouse Adipose Depots.” Journal of Visualized Experiments (149): e59499. doi:https://doi.org/10.3791/59499.
- Blaser, H., C. Dostert, T. W. Mak, and D. Brenne. 2016. “TNF and ROS Crosstalk in Inflammation.” Trends in Cell Biology 26 (4): 249–261. doi:https://doi.org/10.1016/j.tcb.2015.12.002.
- Bulten, B. F., M. Sollini, R. Boni, K. Massri, L.-F. de Geus-Oei, H. W. M. van Laarhoven, R. H. J. A. Slart, and P. A. Erba. 2019. “Cardiac Molecular Pathways Influenced by Doxorubicin Treatment in Mice.” Scientific Reports 9 (1): 2514. doi:https://doi.org/10.1038/s41598-019-38986-w.
- Cataldi, M., C. Vigliotti, T. Mosca, M. R. Cammarota, and D. Capone. 2017. “Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.” International Journal of Molecular Sciences 18 (6): 1249. doi:https://doi.org/10.3390/ijms18061249.
- Chanan-Khan, A., J. Szebeni, S. Savay, L. Liebes, N. M. Rafique, C. R. Alving, and F. M. Muggia. 2003. “Complement Activation following First Exposure to Pegylated Liposomal Doxorubicin (Doxil): Possible Role in Hypersensitivity Reactions.” Annals of Oncology 14 (9): 1430–1437. doi:https://doi.org/10.1093/annonc/mdg374.
- Chen, B.-M., Y.-C. Su, C.-J. Chang, P.-A. Burnouf, K.-H. Chuang, C.-H. Chen, T.-L. Cheng, Y.-T. Chen, J.-Y. Wu, and S.-R. Roffler. 2016. “Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals.” Analytical Chemistry 88 (21): 10661–10666. doi:https://doi.org/10.1021/acs.analchem.6b03109.
- Chen, J., J. Ding, Y. Wang, J. Cheng, S. Ji, X. Zhuang, and X. Chen. 2017. “Sequentially Responsive Shell-Stacked Nanoparticles for Deep Penetration into Solid Tumors.” Advanced Materials 29 (32): 1701170. doi:https://doi.org/10.1002/adma.201701170.
- Chitambar, Ch R. 2016. “Gallium and Its Competing Roles with Iron in Biological Systems.” BBA Molecular Cell Research. 1863 (8): 2044–2053. doi:https://doi.org/10.1016/j.bbamcr.2016.04.027.
- Choi, Ch J. J., J. E. Zuckerman, P. Webster, and M. E. Davi. 2011. “Targeting Kidney Mesangium by Nanoparticles of Defined Size.” Proceedings of the National Academy of Sciences of the United States of America 108 (16): 6656–6661. doi:https://doi.org/10.1073/pnas.1103573108.
- Chono, S., T. Tanino, T. Seki, and K. Morimoto. 2007. “Uptake Characteristics of Liposomes by Rat Alveolar Macrophages: Influence of Particle Size and Surface Mannose Modification.” The Journal of Pharmacy and Pharmacology 59 (1): 75–80. doi:https://doi.org/10.1211/jpp.59.1.0010.
- Chow, T.-H., Y.-Y. Lin, J.-J. Hwang, H.-E. Wang, Y.-L. Tseng, S.-J. Wang, R.-S. Liu, W.-J. Lin, C.-S. Yang, and G. Ting. 2009. “Improvement of Biodistribution and Therapeutic Index via Increase of Polyethylene Glycol on Drug-Carrying Liposomes in an HT-29/Luc Xenografted Mouse Model.” Antaicancer Research 29 (6): 2122–2120.
- Córdoba-Adaya, Julio César, Rigoberto Oros-Pantoja, Eugenio Torres-García, Enrique Morales-Ávila, Liliana Aranda-Lara, Jonnathan G. Santillán-Benítez, Neri O. Hernández-Herrera, Gloria Otero, and Keila Isaac-Olivé. 2021. “Evaluation of Doxorubicin-Induced Early Multi-Organ Toxicity in Male CD1 Mice by Biodistribution of 18F-FDG and 67Ga-Citrate. Pilot study.” Toxicology Mechanisms and Methods 31 (7): 546–548. doi:https://doi.org/10.1080/15376516.2021.1937420.
- Desai, V. G., J. C. Kwekel, V. Vijay, C. L. Moland, E. H. Herman, T. Lee, T. Han, et al. 2014. “Early Biomarkers of Doxorubicin-Induced Heart Injury in a Mouse Model.” Toxicology and Applied Pharmacology 281 (2): 221–229. doi:https://doi.org/10.1016/j.taap.2014.10.006.
- Eirin, A., A. Lerman, and L. O. Lerman. 2017. “The Emerging Role of Mitochondrial Targeting in Kidney Disease.” Handbook of Experimental Pharmacology 240: 229–250. doi:https://doi.org/10.1007/164_2016_6.
- Eralp, Y., X. Wang, J.-P. Wang, M. F. Maughan, J. M. Polo, and L. B. Lachman. 2004. “Doxorubicin and Paclitaxel Enhance the Antitumor Efficacy of Vaccines Directed against HER 2/neu in a Murine Mammary Carcinoma Model.” Breast Cancer Research 6 (4): R275–R283. doi:https://doi.org/10.1186/bcr787.
- Ghigo, A., M. Li, and E. Hirsch. 2016. “New Signal Transduction Paradigms in Anthracycline-Induced Cardiotoxicity.” Biochimica et Biophysica Acta 1863 (7 Pt B): 1916–1925. doi:https://doi.org/10.1016/j.bbamcr.2016.01.021.
- Ghio, A. J., E. L. Turi, F. Yang, L. M. Garrick, and M. D. Garrick. 2006. “Iron Homeostasis in the Lung.” Biological Research 39 (1): 67–77. doi:https://doi.org/10.4067/s0716-97602006000100008.
- Giraudo, Chiara, Laura Evangelista, Anna Sara Fraia, Amalia Lupi, Emilio Quaia, Diego Cecchin, and Massimiliano Casali. 2020. “Molecular Imaging of Pulmonary Inflammation and Infection.” International Journal of Molecular Sciences 21 (3): 894. doi:https://doi.org/10.3390/ijms21030894.
- Hajra, S., A. R. Patra, A. Basu, and S. Bhattacharya. 2018. “Prevention of Doxorubicin (DOX)-Induced Genotoxicity and Cardiotoxicity: Effect of Plant Derived Small Molecule Indole-3-Carbinol (I3C) on Oxidativestress and Inflammation.” Biomedicine & Pharmacotherapy 101: 228–243. doi:https://doi.org/10.1016/j.biopha.2018.02.088.
- Hoene, M., J. Li, H.-U. Haring, C. Weigert, G. Xu, and R. Lehmann. 2014. “The Lipid Profile of Brown Adipose Tissue is Sex-Specific in Mice.” Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1841 (10): 1563–1570. doi:https://doi.org/10.1016/j.bbalip.2014.08.003.
- Huang, L., K. Zhang, Y. Guo, F. Huang, K. Yang, L. Chen, K. Huang, F. Zhang, Q. Long, and Q. Yang. 2017. “Honokiol Protects against Doxorubicin Cardiotoxicity via Improving Mitochondrial Function in Mouse Hearts.” Scientific Reports 7 (1): 11989. doi:https://doi.org/10.1038/s41598-017-12095-y.
- Inglut, C. T., A. J. Sorrin, T. Kuruppu, S. Vig, J. Cicalo, H. Ahmad, and J-Ch. Huang. 2020. “Immunological and Toxicological Considerations for the Design of Liposomes.” Nanomaterials 10 (2): 190. doi:https://doi.org/10.3390/nano10020190.
- Jadapalli, Jeevan Kumar, Griffin W. Wright, Vasundhara Kain, Mohammad Asif Sherwani, Ravi Sonkar, Nabiha Yusuf, and Ganesh V. Halade. 2018. “Doxorubicin Triggers Splenic Contraction and Irreversible Dysregulation of COX and LOX that Alters the Inflammation-Resolution Program in the Myocardium.” American Journal of Physiology. Heart and Circulatory Physiology 315 (5): H1091–H1100. doi:https://doi.org/10.1152/ajpheart.00290.2018.
- Kong, W.-N., K.-M. Niu, L. Ge, N. Zhang, S.-F. Yan, W.-B. Chen, Y.-Z. Chang, and S.-E. Zhao. 2014. “Sex Differences in Iron Status and Hepcidin Expression in Rats.” Biological Trace Element Research 160 (2): 258–267. doi:https://doi.org/10.1007/s12011-014-0051-3.
- Kullenberg, F., O. Degerstedt, C. Calitz, N. Pavlovic, D. Balgoma, J. Gråsjö, E. Sjögren, M. Hedeland, F. Heindryckx, and H. Lennernäs. 2021. “In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma.” Cells 10 (7): 1717. doi:https://doi.org/10.3390/cells10071717.
- Landesman-Milo, D., and D. Peer. 2012. “Altering the Immune Response with Lipid-Based Nanoparticles.” Journal of Controlled Release 161 (2): 600–608. doi:https://doi.org/10.1016/j.jconrel.2011.12.034.
- Lee, Y. K., E. J. Choi, T. J. Webster, S. H. Kim, and D. Khang. 2015. “Effect of the Protein Corona on Nanoparticles for Modulating Cytotoxicity and Immunotoxicity.” International Journal of Nanomedicine 10: 97–113. doi:https://doi.org/10.2147/IJN.S72998.
- Liu, S. 2019. “Heart-Kidney Interactions: mechanistic Insights from Animal Models.” American Journal of Physiology. Renal Physiology 316 (5): F974–F985. doi:https://doi.org/10.1152/ajprenal.00624.2017.
- Luo, R., Y. Li, M. He, H. Zhang, H. Yuan, M. Johnson, M. Palmisano, S. Zhou, and D. Sun. 2017. “Distinct Biodistribution of Doxorubicin and the Altered Dispositions Mediated by Different Liposomal Formulations.” International Journal of Pharmaceutics 519 (1–2): 1–10. doi:https://doi.org/10.1016/j.ijpharm.2017.01.002.
- Madla, C. M., F. K. H. Gavins, H. Merchant, M. Orlu, S. Murdan, and A. W. Basit. 2021. “Let's Talk About Sex: Differences in Drug Therapy in Males and Females.” Advanced Drug Delivery Reviews 175: 113804. doi:https://doi.org/10.1016/j.addr.2021.05.014.
- Mathis, D., and S. E. Shoelson. 2011. “Immunometabolism: An Emerging frontier.” Nature Reviews. Immunology 11 (2): 81–83. doi:https://doi.org/10.1038/nri2922.
- Medina, L. A., L. Martínez-Acevedo, C. Juárez-Osornio, P. García-López, J. M. Pérez-Rojas, R. Jurado, and H. Vázquez-Becerra. 2012. “Pharmacological Evaluation of Two Liposomal Doxorubicin Formulations.” Latin American Journal of Pharmacy 31 (6): 835–843.
- Meiners, B., C. Shenoy, and B. N. Zordoky. 2018. “Clinical and Preclinical Evidence of Sex-Related Differences in Anthracycline-Induced Cardiotoxicity.” Biology of Sex Differences 9 (1): 38. doi:https://doi.org/10.1186/s13293-018-0198-2.
- Mettler, F. A. Jr., and M. J. Guiberteau. 2012. “Inflammation and Infection Imaging.” In Essentials of Nuclear Medicine Imaging. 6th ed., Cap 12, 397–412. Elsevier Inc.
- Mirzaaghasi, A., Y. Han, S.-H. Ahn, C. Choi, and J.-H. Park. 2021. “Biodistribution and Pharmacokinectics of Liposomes and Exosomes in a Mouse Model of Sepsis.” Pharmaceutics 13 (3): 427. doi:https://doi.org/10.3390/pharmaceutics13030427.
- Neves, J., T. Haider, M. Gassmann, and M. U. Muckenthaler. 2019. “Iron Homeostasis in the Lungs—A Balance between Health and Disease.” Pharmaceuticals 12 (1): 5. doi:https://doi.org/10.3390/ph12010005.
- Nijen Twilhaar, N. K., Czentner, L., Grabowska, J. Affandi, A. J. Jerry Lau Ch, Y. Olesek, K. Kalay, H, et al. 2020. “Optimization of Liposomes for Antigen Targeting to Splenic CD169+ Macrophages.” Pharmaceutics 12 (12): 1138. doi:https://doi.org/10.3390/pharmaceutics12121138.
- Norma Oficial Mexicana-NOM-062-ZOO-1999. 2002. “Especificaciones Técnicas Para la Producción, Cuidado y Uso de Los Animales de Laboratorio.” Gac Méd Méx 138 (3): 295–298.
- Pardue, R. L., and C. A. White. 1997. “Pharmacokinetic Evaluation of Liposomal Encapsulated Ampicillin in Male and Female Rats.” Biopharmaceutics & Drug Disposition 18 (4): 279–292. aid-bdd989 > 3.0.co;2-g. doi:https://doi.org/10.1002/(sici)1099-081x(199705)18:4 < 279:.
- Patel, B., N. Gupta, and F. Ahsan. 2015. “Particle Engineering to Enhance or Lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome.” European Journal of Pharmaceutics and Biopharmaceutics 89: 163–174. doi:https://doi.org/10.1016/j.ejpb.2014.12.001.
- Piao, Y., Y. Liu, and X. Xie. 2013. “Change Trends of Organ Weight Background Data in Sprague Dawley Rats at Different Ages.” Journal of Toxicologic Pathology 26 (1): 29–34. doi:https://doi.org/10.1293/tox.26.29.
- Pugazhendhi, A., T. N. J. I. Edison, B. K. Velmurugan, J. A. Jacob, and I. Karuppusamy. 2018. “Toxicity of Doxorubicin (Dox) to Different Experimental Organ Systems.” Life Sciences 200: 26–30. doi:https://doi.org/10.1016/j.lfs.2018.03.023.
- Rafiyath, S. M., M. Rasul, B. Lee, G. Wei, G. Lamba, and D. Liu. 2012. “Comparison of Safety and Toxicity of Liposomal Doxorubicin vs. conventional Anthracyclines: A Meta-Analysis.” Experimental Hematology & Oncology 1 (1): 10. doi:https://doi.org/10.1186/2162-3619-1-10.
- Robinson, Mark W., Cathal Harmon, and Cliona O'Farrelly. 2016. “Liver Immunology and Its Role in Inflammation and Homeostasis.” Cellular & Molecular Immunology 13 (3): 267–276. doi:https://doi.org/10.1038/cmi.2016.3.
- Rosales, C. 2018. “Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types?” Frontiers in Physiology 9: 113. doi:https://doi.org/10.3389/fphys.2018.00113.
- Silljé, H. H. W., and R. A. de Boer. 2017. “ Heart Failure: Macrophages Take Centre Stage in the Heart-Brain-Kidney Axis.” Nature Reviews. Nephrology 13 (7): 388–390. doi:https://doi.org/10.1038/nrneph.2017.73.
- Siqueiros-Cendón, T., S. Arévalo-Gallegos, B. F. Iglesias-Figueroa, I. A. García-Montoya, J. Salazar-Martínez, and Q. Rascón-Cruz. 2014. “Immunomodulatory Effects of Lactoferrin.” Acta Pharmacologica Sinica 35 (5): 557–566. doi:https://doi.org/10.1038/aps.2013.200.
- Smits, E. A. W., J. A. Soetekouw, E. H. E. Pieters, C. J. P. Smits, N. de Wijs-Rot, and H. Vromans. 2019. “The Availability of Drug by Liposomal Drug Delivery: Individual Kinetics and Tissue Distribution of Encapsulated and Released Drug in Mice After Administration of PEGylated Liposomal Prednisolone Phosphate.” Investigational New Drugs 37 (5): 890–901. doi:https://doi.org/10.1007/s10637-018-0708-4.
- Soloman, Rebecca, and Alberto A. Gabizon. 2008. “Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin.” Clinical Lymphoma & Myeloma 8 (1): 21–32. doi:https://doi.org/10.3816/clm.2008.n.001.
- Suk, J. S., Q. Xu, N. Kim, J. Hanes, and L. M. Ensign. 2016. “PEGylation as a Strategy for Improving Nanoparticle-Based Drug and Gene Delivery.” Advanced Drug Delivery Reviews 99 (Pt A): 28–51. doi:https://doi.org/10.1016/j.addr.2015.09.012.
- Suzuki, Y. A., and B. Lönnerdal. 2004. “Baculovirus Expression of Mouse Lactoferrin Receptor and Tissue Distribution in the Mouse.” Biometals 17 (3): 301–309. doi:https://doi.org/10.1023/B:BIOM.0000027709.42733.e4.
- Szebeni, J., L. Baranyi, S. Savay, M. Bodo, D. S. Morse, M. Basta, G. L. Stahl, R. Bunger, and C. R. Alving. 2000. “Liposome-Induced Pulmonary Hypertension: Properties and Mechanism of a Complement-Mediated Pseudoallergic Reaction.” American Journal of Physiology. Heart and Circulatory Physiology 279 (3): H1319–H1328. doi:https://doi.org/10.1152/ajpheart.2000.279.3.H1319.
- Szebeni, J., C. R. Alving, L. Rosivall, R. Bünger, L. Baranyi, P. Bedöcs, M. Tóth, and Y. Barenholz. 2007. “Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles.” Journal of Liposome Research 17 (2): 107–117. doi:https://doi.org/10.1080/08982100701375118.
- National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. 2011. Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press (US). Available from: https://www.ncbi.nlm.- nih.gov/books/NBK54050/
- Toriihara, Akira, Hiromitsu Daisaki, Akihiro Yamaguchi, Katsuya Yoshida, Jun Isogai, and Ukihide Tateishi. 2018. “Applying Standardized Uptake Values in Gallium-67-Citrate Single-Photon Emission Computed Tomography/Computed Tomography Studies and Their Correlation with Blood Test Results in Representative Organs.” Nuclear Medicine Communications 39 (8): 720–724. doi:https://doi.org/10.1097/MNM.0000000000000868.
- Tsan, M.-F. 1985. “Mechanism of Gallium-67 Accumulation in Inflammatory Lesions.” Journal of Nuclear Medicine 26 (1): 88–92.
- Vail, D. M., M. A. Amantea, G. T. Colbern, F. J. Martin, R. A. Hilger, and P. K. Working. 2004. “Pegylated Liposomal Doxorubicin: Proof of Principle Using Preclinical Animal Models and Pharmacokinetic Studies.” Seminars in Oncology 31 (6 Suppl 13): 16–35. doi:https://doi.org/10.1053/j.seminoncol.2004.08.002.
- Vallabhajosula, S., R. P. Killeen, and J. R. Osborne. 2010. “Altered Biodistribution of Radiopharmaceuticals: Role of Radiochemical/Pharmaceutical Purity, Physiological, and Pharmacologic Factors.” Seminars in Nuclear Medicine 40 (4): 220–241. doi:https://doi.org/10.1053/j.semnuclmed.2010.02.004.
- van Asbeck, A. H., J. Dieker, M. Boswinkel, J. van der Vlag, and R. Brock. 2020. “Kidney-Targeted Therapies: A Quantitative Perspective.” Journal of Controlled Release 328: 762–775. doi:https://doi.org/10.1016/j.jconrel.2020.09.022.
- Vanbever, Rita, Cristina Loira-Pastoriza, Nicolas Dauguet, Caroline Hérin, Saloua Ibouraadaten, Kevin Vanvarenberg, Bernard Ucakar, Donatienne Tyteca, and François Huaux. 2019. “Cationic Nanoliposomes Are Efficiently Taken up by Alveolar Macrophages but Have Little Access to Dendritic Cells and Interstitial Macrophages in the Normal and CpG-Stimulated Lungs.” Molecular Pharmaceutics 16 (5): 2048–2059. doi:https://doi.org/10.1021/acs.molpharmaceut.9b00033.
- Veiras, L. C., A. C. C. Girardi, J. Curry, L. Pei, D. L. Ralph, A. Tran, R. C. Castelo-Branco, et al. 2017. “Sexual Dimorphic Pattern of Renal Transporters and Electrolyte Homeostasis.” Journal of the American Society of Nephrology 28 (12): 3504–3517. doi:https://doi.org/10.1681/ASN.2017030295.
- Williams, R. M., E. A. Jaimes, and D. A. Heller. 2016. “Nanomedicines for Kidney Diseases.” Kidney International 90 (4): 740–745. doi:https://doi.org/10.1016/j.kint.2016.03.041.
- Xu, W., H. Deng, S. Hu, Y. Zhang, L. Zheng, M. Liu, Y. Chen, J. Wei, H. Yang, and X. Lv. 2021. “Role of Ferroptosis in Lung Diseases.” Journal of Inflammation Research 14: 2079–2090. doi:https://doi.org/10.2147/JIR.S307081.
- Yang, J., Z. Yin, Y. Chang, H. Wang, J.-F. Xu, and X. Zhang. 2021. “Tumor Acidity-Induced Charge-Reversal Liposomal Doxorubicin with Enhanced Cancer Cell Uptake and Anticancer Activity.” Giant 6: 100052. doi:https://doi.org/10.1016/j.giant.2021.100052.
- Yu, Yingying, Li Jiang, Hao Wang, Zhe Shen, Qi Cheng, Pan Zhang, Jiaming Wang, et al. 2020. “Hepatic Transferrin Plays a Role in Systemic Iron Homeostasis and Liver Ferroptosis.” Blood 136 (6): 726–739. doi:https://doi.org/10.1182/blood.2019002907.
- Zamora, E., A. Y. Valdivia, B. Zalta, and L. S. Zuckier. 2020. “[67Ga] Ga-Citrate and COVID-19-Associated Pneumonia: An Unexpected Absence of Uptake.” European Journal of Nuclear Medicine and Molecular Imaging 47 (9): 2207–2208. doi:https://doi.org/10.1007/s00259-020-04886-9.
- Zhao, N., M. C. Woodle, and A. J. Mixson. 2018. “Advances in Delivery Systems for Doxorubicin.” Journal of Nanomedicine & Nanotechnology 9 (5): 519. doi:https://doi.org/10.4172/2157-7439.1000519.
- Ziessman, H. A., J. P. O'Malley, and J. H. Thrall, eds. 2014. “Infection and Inflammation. Chapter 14.” In Nuclear Medicine. 4th ed., 322–349. Elsevier Saunders. eBook ISBN: 9780323112925
- Zuckier, L. S., A. Y. Valdivia, and E. Zamora. 2020. “Does Gallium-Citrate Have yet Another Story to Tell? Lessons Relevant to the COVID-19 Era.” European Journal of Nuclear Medicine and Molecular Imaging 47 (9): 2059–2061. doi:https://doi.org/10.1007/s00259-020-04890-z.